Outcome Comparison between Solumedrol and Dexamethasone in Moderate to Severe COVID Disease

Authors

  • Aleena Muzaffar, Saima Aslam, Sarmad Khalil

DOI:

https://doi.org/10.53350/pjmhs221651264

Keywords:

COVID-19, Patients, Inflammation, Markers, Lungs, Pneumonia

Abstract

Introduction: Covid 19 is a disease caused by a virus belonging to SARS Co V2 family of viruses. It primarily effects the lungs resulting in inflammation and pneumonia.

Objectives: The main objective of the study is to compare the outcomes and efficacy of solumedrol and dexamethasone in moderate to severe COVID disease.

Material and methods: This cross sectional study was conducted in THQ Hospital Safdarabad during 2020 to 2021. The data was collected from 100 COVID-19 patients diagnosed with moderate to severe condition of the diseases. The data was collected through non-probability consecutive sampling technique.

Results: The data was collected from 100 patients of moderate to severe COVID-19 condition. There were 35 patients in group I and 65 patients’ group II. The mean age for dexamethasone (group II) was 55.41 ± 10.4 years and solumedrol (group I) was 56.86 ± 9.3 years.

Conclusion: It is concluded that both drugs dexamethasone and solumedrol are effective in improving clinical and biochemical parameters of moderate to severe covid 19 disease. 

Downloads

How to Cite

Aleena Muzaffar, Saima Aslam, Sarmad Khalil. (2022). Outcome Comparison between Solumedrol and Dexamethasone in Moderate to Severe COVID Disease. Pakistan Journal of Medical & Health Sciences, 16(05), 1264. https://doi.org/10.53350/pjmhs221651264